Gabriel Kim

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Michael Roden, Jianping Weng, Jens Eilbracht et al. · The Lancet Diabetes & Endocrinology · 2013 · 446 citations

Medicine, Endocrinology, Pharmacology +15

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller et al. · The Lancet Diabetes & Endocrinology · 2014 · 379 citations

Medicine, Pharmacology, Pharmacotherapy +11

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

Julio Rosenstock, Ante Jelaska, Guillaume Frappin et al. · Diabetes Care · 2014 · 365 citations

Medicine, Pharmacology, Pharmacotherapy +17

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

Michael Roden, Ludwig Merker, Anita Vedel Christiansen et al. · Cardiovascular Diabetology · 2015 · 134 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

Christopher S. Kovács, Veeraswamy Seshiah, Ludwig Merker et al. · Clinical Therapeutics · 2015 · 111 citations

Medicine, Pharmacology, Pharmacotherapy +14